Melanotan II vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan II
Melanotan II is a synthetic peptide analog of α-MSH with broader receptor activity than Melanotan I. It produces tanning effects and has notable effects on sexual function and appetite suppression.
Full details →Retatrutide
Retatrutide (LY3437943) is a first-in-class triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. Developed by Eli Lilly, it is currently in Phase 3 clinical trials and has demonstrated the highest weight loss of any obesity medication to date — up to 28.7% body weight reduction at 48 weeks. The triple-receptor mechanism represents the next evolution beyond dual agonists like tirzepatide.
Full details →Side-by-Side Comparison
| Aspect | Melanotan II | Retatrutide |
|---|---|---|
| Mechanism | Non-selective melanocortin receptor agonist affecting MC1R (tanning), MC3R and MC4R (sexual function and appetite). This broader activity explains its multiple effects beyond tanning. | Retatrutide is a synthetic peptide that activates three incretin/metabolic hormone receptors: (1) GLP-1 receptor — appetite suppression, insulin secretion, delayed gastric emptying, (2) GIP receptor — enhanced insulin sensitivity, improved fat metabolism, (3) Glucagon receptor — increased energy expenditure, hepatic fat mobilization, thermogenesis. The glucagon receptor component is the key differentiator, adding an energy-expenditure mechanism absent from GLP-1 and dual GIP/GLP-1 agonists. The molecule uses a C20 fatty diacid for albumin binding, enabling once-weekly dosing. |
| Typical Dosage | Typical protocols: 0.25-0.5mg daily during loading phase for 1-2 weeks, then 0.5-1mg before UV exposure for maintenance. Start low to assess tolerance. | Phase 2 trial doses: 0.5 mg, 4 mg, 8 mg, and 12 mg weekly. The 12 mg dose produced maximum weight loss (28.7%). Phase 3 trials are evaluating doses up to 12 mg. Dose escalation schedule similar to other GLP-1s (start low, increase every 4 weeks). Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Subcutaneous injection. Usually combined with UV exposure for tanning effects. Nasal spray formulations exist but have lower bioavailability. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled single-dose pens. Not yet commercially available — estimated FDA approval ~2027-2028. |
| Side Effects | Nausea (common initially), facial flushing, spontaneous erections, increased libido, appetite suppression, and mole darkening. | Phase 2 data: nausea (up to 25%), diarrhea (up to 22%), vomiting (up to 15%), constipation, decreased appetite. GI side effects were dose-dependent and generally mild-to-moderate. Lower rates of nausea compared to semaglutide, potentially due to GIP component. Increased heart rate observed at higher doses. |
| Best For |
Key Differences
Unique to Melanotan II:
Unique to Retatrutide:
Detailed Analysis
Commonalities
Both Melanotan II and Retatrutide are commonly used for Fat Loss.
Which Should You Choose?
Retatrutide has stronger evidence for Fat Loss.
Ready to Learn More?
Looking for trusted sources?